North America Molecular Diagnostics Market

The North America molecular diagnostics market is expected to grow from US$ 8,056.48 million in 2022 to US$ 20,740.38 million by 2030. It is estimated to grow at a CAGR of 12.5% from 2022 to 2030.     

Development of New Products and Increase in Demand for Point-of-Care Testing Fuels North America Molecular Diagnostics Market

Point-of-care testing is a branch of medicine with a rapidly evolving analytical scope and clinical application. Point-of-care testing solution providers offer products for various evaluations, ranging from blood glucose measurement to viscoelastic coagulation assays. Eliminating the time of transportation and preparation of clinical samples, these tests enable professionals to make clinical decisions about additional testing or therapy in less time. This emerging healthcare solution is being aggressively adopted by patients and healthcare service providers. Point-of-care assays are extensively used in therapeutics, diagnostics, and patient monitoring applications, among others. Moreover, point-of-care products and services help healthcare providers in meeting patients’ demand for at-home medical care. These products and services proved specifically helpful during the COVID-19 pandemic by allowing patients to take tests from their homes instead of traveling to diagnostic or treatment facilities, thereby lowering the risk of infection. Thus, the rising demand for point-of-care testing benefits the molecular diagnostics market.

North America Molecular Diagnostics Market Overview

The North America molecular diagnostics market has been segmented into the US, Canada, and Mexico. The increasing adoption of technologically advanced products, rise in research & development activities, presence of large healthcare businesses, and growing use of molecular diagnostics are among the key factors propelling the growth of the molecular diagnostics market in this region. The US held the largest share of the North America molecular diagnostics market in 2022.

North America Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Million)

North America Molecular Diagnostics Market Segmentation

The North America molecular diagnostics market is segmented into disease area, technology, product and services, end user, and country.

Based on disease area, the North America molecular diagnostics market is segmented into infectious disease, oncology, genetic testing, cardiac diseases, immune system disorders, and others. The infectious disease segment registered the largest North America molecular diagnostics market share in 2022.

Based on technology, the North America molecular diagnostics market is segmented into polymerase chain reaction (PCR), in situ hybridization, isothermal nucleic acid amplification technology (INAAT), DNA sequencing and next-generation sequencing (NGS), DNA microarrays, and others. The polymerase chain reaction (PCR) segment registered the largest North America molecular diagnostics market share in 2022. The polymerase chain reaction (PCR) is further subsegmented into RT-PCR, qPCR, multiplex PCR, and others.

Based on product and services, the North America molecular diagnostics market is segmented into assays and kits, instruments, and services and software. The assays and kits segment registered the largest North America molecular diagnostics market share in 2022.

Based on end users, the North America molecular diagnostics market is segmented into diagnostic laboratories, hospitals and clinics, research and academic institutes, and others. The diagnostic laboratories segment held the largest North America molecular diagnostics market share in 2022.

Based on country, the North America molecular diagnostics market has been categorized into the US, Canada, and Mexico. The US dominated the North America molecular diagnostics market in 2022.  

Abbott Laboratories, Agilent Technologies Inc, Thermo Fisher Scientific Inc, F. Hoffmann-La Roche Ltd, Qiagen NV, bioMerieux SA, Illumina Inc, Danaher, Siemens Healthineers AG, Novartis AG, and TBG Diagnostics Limited are some of the leading companies operating in the North America molecular diagnostics market.